CASI PHARMACEUTICALS INC.

🇰🇾Cayman Islands

Country: 🇰🇾Cayman Islands

Ownership: Public

Employees: 243

Market Cap: $100.6M

Website: http://www.casipharmaceuticals.com

Clinical Trials

CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CID-103

First Posted Date: 2021-02-17

Last Posted Date: 2023-03-02

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 10

Registration Number: NCT04758767

Locations: 🇫🇷
CHU de Nantes - Hôpital Hôtel-Dieu, Nantes, France
🇫🇷
CHU Rennes - Pontchaillou, Rennes, France
🇫🇷
Gustave Roussy Cancer Center, Villejuif Cedex, France

and more 1 locations

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Phase 2

Completed

Conditions: Advanced Fibrolamellar Carcinoma
Advanced Adult Hepatocellular Carcinoma

Interventions: Drug: ENMD-2076

First Posted Date: 2014-09-09

Last Posted Date: 2018-09-06

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 37

Registration Number: NCT02234986

Locations: 🇺🇸
CASI Site 04, Aurora, Colorado, United States
🇺🇸
CASI Site 02, Boston, Massachusetts, United States
🇺🇸
Casi Site 01, New York, New York, United States

and more 2 locations

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: ENMD-2076

First Posted Date: 2012-07-12

Last Posted Date: 2017-06-26

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 41

Registration Number: NCT01639248

Locations: 🇨🇳
Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Inidiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Fallopian Cancer
Ovarian Cancer

Interventions: Drug: ENMD-2076

First Posted Date: 2010-04-15

Last Posted Date: 2014-08-06

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 64

Registration Number: NCT01104675

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States

and more 3 locations

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Phase 1

Completed

Conditions: Relapsed or Refractory Hematological Malignancies

Interventions: Drug: ENMD-2076

First Posted Date: 2009-05-20

Last Posted Date: 2011-08-04

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT00904787

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Study of ENMD-2076 in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ENMD-2076

First Posted Date: 2008-12-10

Last Posted Date: 2023-02-06

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 13

Registration Number: NCT00806065

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: ENMD-2076

First Posted Date: 2008-04-15

Last Posted Date: 2023-02-06

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 67

Registration Number: NCT00658671

Locations: 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Phase 1 Study of MKC-1 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: MKC-1

First Posted Date: 2008-04-11

Last Posted Date: 2009-11-25

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT00656461

Locations: 🇺🇸
U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Endometrial Cancer

Interventions: Drug: MKC-1

First Posted Date: 2008-02-06

Last Posted Date: 2012-01-20

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 44

Registration Number: NCT00607607

Locations: 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada

and more 3 locations

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed Multiple Myeloma
Plateau Phase Multiple Myeloma

Interventions: Drug: 2-methoxyestradiol

First Posted Date: 2008-01-14

Last Posted Date: 2009-02-26

Lead Sponsor: CASI Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT00592579

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy